Author | Edwin M. Posadas, MD

Articles

Third-Line Treatment Options for Kidney Cancer

September 15, 2016

Effectively, the field has tested agents for metastatic disease in only two clinical settings: primary management of metastatic disease (first-line) and after progression with a first-line therapy (second-line); however, there are no category 1 data that support the use of any agent in the third-line setting.